KELLIE VAUGHN: Open Payments
NPI 1245705698 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,825 in 91 payments from 12 companies in 2025. Trend: 2023 $1,814 · 2024 $995 · 2025 $1,825
Food & beverage: $1,825
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $583 |
| Otsuka America Pharmaceutical, Inc. | 11 | $251 |
| ABBVIE INC. | 22 | $244 |
| Vanda Pharmaceuticals Inc. | 6 | $151 |
| E.R. Squibb & Sons, L.L.C. | 5 | $113 |
| Axsome Therapeutics, Inc. | 4 | $109 |
| Lundbeck LLC | 4 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Neurocrine BioSciences, Inc. | 3 | $66 |
| Alkermes, Inc. | 3 | $63 |
Products named: CAPLYTA, REXULTI, VRAYLAR, FANAPT, COBENFY, Auvelity, TRINTELLIX, INGREZZA.
Industry payments across AL — which companies pay providers there.
